Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
David  Morgan

David Morgan, M.D.

Associate Professor of Medicine (Hematology and Oncology)
Hematologist/Oncologist

Profile

Dr. Morgan is board certified by the American Board of Internal Medicine in medical oncology and specializes in hematological malignancies including leukemia, lymphoma, Hodgkin's Disease and non-Hodgkin's Lymphoma. He has a particular clinical interest in lymphoma in the setting of immunosuppression and treats the majority of patients with AIDS-related lymphoma.
Read more...

Dr. Morgan is board certified by the American Board of Internal Medicine in medical oncology and specializes in hematological malignancies including leukemia, lymphoma, Hodgkin's Disease and non-Hodgkin's Lymphoma. He has a particular clinical interest in lymphoma in the setting of immunosuppression and treats the majority of patients with AIDS-related lymphoma. Dr. Morgan is involved in a variety of clinical trials including studying new types of lymphoma treatments such as radioimmunotherapy and vaccine therapies. He is very active both within Vanderbilt University and externally through a number of professional societies. Dr. Morgan has been a member of the Vanderbilt University Medical Center faculty since October 1997.

Education
  • M.D.: Vanderbilt University School of Medicine, 1990
  • Internship:  Internal Medicine, Yale University School of Medicine, 1991
  • Residency:  Internal Medicine, Yale University School of Medicine, 1993
  • Fellowship:  Medical Oncology, Stanford University School of Medicine, 1997
Research Description

.

Publications
  • Huntington SF, Talbott MS, Greer JP, Morgan DS, Reddy N. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leuk. Lymphoma [print-electronic]. 2012 Aug; 53(8): 1461-8. PMID: 22260160, DOI: 10.3109/10428194.2012.658793, ISSN: 1029-2403.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22260160.
  • Chinratanalab W, Reddy N, Greer JP, Morgan D, Engelhardt B, Kassim A, Brandt SJ, Jagasia M, Goodman S, Savani BN. Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies. Exp. Hematol [print-electronic]. 2012 Jun; 40(6): 431-5. PMID: 22269114, PMCID: PMC4067702, PII: S0301-472X(12)00016-1, DOI: 10.1016/j.exphem.2012.01.014, ISSN: 1873-2399.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22269114.
  • Reddy N, Greer JP, Goodman S, Kassim A, Morgan DS, Chinratanalab W, Brandt S, Englehardt B, Oluwole O, Jagasia MH, Savani BN. Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Exp. Hematol [print-electronic]. 2012 May; 40(5): 359-66. PMID: 22269117, PII: S0301-472X(12)00014-8, DOI: 10.1016/j.exphem.2012.01.012, ISSN: 1873-2399.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22269117.
  • Reddy N, Abel TW, Jagasia M, Morgan D, Weaver K, Greer J. Progressive multifocal leukoencephalopathy in a patient with follicular lymphoma treated with multiple courses of rituximab. Leuk. Lymphoma. 2009 Mar; 50(3): 460-2. PMID: 19266387, PII: 909254836, DOI: 10.1080/10428190802695827, ISSN: 1029-2403.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19266387.
  • Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H, Engelhardt B, Goodman S, Greer J, Kassim A, Morgan D, Ruffner K, Schuening F. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol. Blood Marrow Transplant [print-electronic]. 2007 Oct; 13(10): 1207-15. PMID: 17889358, PII: S1083-8791(07)00338-2, DOI: 10.1016/j.bbmt.2007.07.001, ISSN: 1083-8791.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17889358.
  • Engelhardt BG, Holland DW, Brandt SJ, Chinratanalab W, Goodman SA, Greer JP, Jagasia MH, Kassim AA, Morgan DS, Ruffner KL, Schuening FG, Wolff S, Bitting R, Sulur P, Stein RS. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes. Leuk. Lymphoma. 2007 Sep; 48(9): 1728-35. PMID: 17786708, PII: 781802102, DOI: 10.1080/10428190701534374, ISSN: 1042-8194.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17786708.
  • Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, Chen H, Schuening FG. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant. 2005 Jun; 35(12): 1165-9. PMID: 15880129, PII: 1704994, DOI: 10.1038/sj.bmt.1704994, ISSN: 0268-3369.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15880129.
  • Jagasia M, Morgan D, Goodman S, Hamilton K, Kinney M, Shyr Y, Stein R, Zic J, Greer J. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk. Lymphoma. 2004 Nov; 45(11): 2261-7. PMID: 15512815, PII: VDJ562CRM6ENDF6H, DOI: 10.1080/10428190412331272749, ISSN: 1042-8194.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15512815.
  • Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, Hallahan DE. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2003 Oct 10/1/2003; 57(2): 307-15. PMID: 12957239, PII: S0360301603005996, ISSN: 0360-3016.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12957239.
  • Arrowsmith ER, Macon WR, Kinney MC, Stein RS, Goodman SA, Morgan DS, Flexner JM, Cousar JB, Jagasia MH, McCurley TL, Greer JP. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk. Lymphoma. 2003 Feb; 44(2): 241-9. PMID: 12688340, DOI: 10.1080/1042819021000030054, ISSN: 1042-8194.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12688340.
  • Delbeke D, Martin WH, Morgan DS, Kinney MC, Feurer I, Kovalsky E, Arrowsmith T, Greer JP. 2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol. 2002 Jan; 4(1): 105-14. PMID: 14538054, PII: S1095039701000589, ISSN: 1536-1632.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/14538054.
  • Stein RS, Wolff SN, Greer JP, Flexner JM, Goodman S, Jagasia M, Brandt SJ, Morgan DS, Arrowsmith E, McCurley TL. Age and cytogenetics as predictors of event free survival in patients with acute non-lymphocytic leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy. Leuk. Lymphoma. 2001 Sep; 42(5): 913-22. PMID: 11697646, DOI: 10.3109/10428190109097710, ISSN: 1042-8194.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11697646.
  • Vusirikala M, Wolff SN, Stein RS, Brandt SJ, Morgan DS, Greer JP, Schuening FG, Dummer JS, Goodman SA. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant. 2001 Aug; 28(3): 265-70. PMID: 11535994, DOI: 10.1038/sj.bmt.1703129, ISSN: 0268-3369.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11535994.
  • Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR, McCurley TL, Wolff SN. Is total body irradiation a necessary component of preparative therapy for autologous transplantation in non-Hodgkin's lymphoma. Leuk. Lymphoma. 2001 Mar; 41(1-2): 97-103. PMID: 11342361, PII: I308J001145, DOI: 10.3109/10428190109057958, ISSN: 1042-8194.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11342361.
  • Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR, McCurley TL, Wolff SN. Limited efficacy of intensified preparative regimens and autologous transplantation as salvage therapy in high grade non-Hodgkin's lymphoma. Leuk. Lymphoma. 2001 Feb; 40(5-6): 521-8. PMID: 11426525, DOI: 10.3109/10428190109097651, ISSN: 1042-8194.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11426525.
  • Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR, McCurley TL, Wolff SN. Is total body irradiation a necessary component of preparative therapy for autologous transplantation in non-Hodgkin's lymphoma. Leukemia and Lymphoma. 2001; 41(1-2)((March)): 97-103.
  • Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR, McCurley TL, Wolff SN. Limited efficacy of intensified preparative regimens and autologous transplantation as salvage therapy in high grade non-Hodgkin's lymphoma. Leukemia and Lymphoma. 2001; 40(5-6):((February)): 521-8.
  • Stein RS, Wolff SN, Greer JP, Flexner JM, Goodman S, Jagasia M, Brandt SJ, Morgan DS, Arrowsmith E, McCurley TL. Age and Cytogenetics as Predictors of Event Free Survival in Patients with Acute Non-Lymphocytic Leukemia Receiving High Dose Cytosine Arabinoside and Daunorubicin as Consolidation Chemotherapy. Leukemia and Lymphoma. 2001; 42(5)((February)): 913-22.
  • Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR, McCurley TL, Wolff SN. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000 Feb; 25(3): 257-62. PMID: 10673696, DOI: 10.1038/sj.bmt.1702132, ISSN: 0268-3369.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10673696.
  • Delbeke D, Morgan DS, Kovalsky E, Dangleis K, Cerci R, Martin WH, Kinney MC, Greer JP. 18F-F1 Fluorodeoxyglucose Imaging With Positron Emission Tomography in the Follow-Up of Patients With Lymphoma. Journal of Nuclear Medicine. 2000; 41(5)(Suppl.): Abstract 276.
  • Delbeke, Morgan DS, Kovalsky E, Dangleis K, Cerci R, Martin WH, Kinney MC, Greer JP. 18F-Fluorodeoxyglucose Imaging with Positron Emission Tomography for Initial Staging of Hodgkin¿s Disease and Lymphoma. Journal of Nuclear Medicine. 2000; ((41(5)(Suppl.))): Abstract 1207.
  • Delbeke, Morgan DS, Kovalsky E, Dangleis K, Cerci R, Martin WH, Kinney MC, Greer JP. 18F-Fluorodeoxyglucose Imaging with Positron Emission Tomography for Initial Staging of Hodgkin¿s Disease and Lymphoma. Journal of Nuclear Medicine. 2000; 41(5)(Suppl.) Abstract: 1207.
  • Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR, McCurley TL, Wolff SN. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin¿s Lymphoma. Bone Marrow Transplantation. 2000; 25(3)((February)): 257-62.
  • Horwitz SM, Ranheim EA, Morgan DS, Horning SJ. Unified Approach to Post-Transplant Lymphoproliferative Disorder (PTLD): Improved Outcome and Analysis of Prognostic Factors. Blood. 1999; 94:10(Suppl. 1) Abstr 2295.
  • Morgan DS, Simpson JF. Non-Hodgkin¿s Lymphoma of the Breast. Textbook of Uncommon Cancer. 1999.
  • Arrowsmith ER, Greer JP, Stein RS, Wolff SN, Goodman SA, Kallianpur AR, Flexner JM, Morgan DS, Kinney MC, Macon WR. Peripheral T-Cell Lymphomas (PTCL): A Clinicopathologic Study of 94 Unselected Patients Using the Revised European American Lymphoma (REAL) Classification. Proc Am Soc Clin Oncol. 1998; 17:A50.
  • Morgan DS, Horning SJ. Indolent Lymphomas. Therapy of Hematopoietic Neoplasia. 1998.